anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Thoracic aortic aneurysm (TAA) is associated with Marfan syndrome (MFS), a connective tissue disorder caused by mutations in fibrillin-1. Sexual dimorphism has been recorded for TAA outcomes in MFS, but detailed studies on the differences in TAA progression in males and females and their relationships to outcomes have not been performed. The aims of this study were to determine sex differences in the diameter dilatation, mechanical properties, and extracellular matrix (ECM) remodeling over time in a severe mouse model (Fbn1mgR/mgR = MU) of MFS-associated TAA that has a shortened life span. Male and female MU and wildtype (WT) mice were used at 1-4 mo of age. Blood pressure and in vivo diameters of the ascending thoracic aorta were recorded using a tail-cuff system and ultrasound imaging, respectively. Ex vivo mechanics and ECM remodeling of the aorta were characterized using a biaxial test system and multiphoton imaging, respectively. We showed that mechanical properties, such as structural and material stiffness, and ECM remodeling, such as elastic and collagen fiber content, correlated with diameter dilatation during TAA progression. Male MU mice had accelerated rates of diameter dilatation, stiffening, and ECM remodeling compared with female MU mice which may have contributed to their decreased life span. The correlation of mechanical properties and ECM remodeling with diameter dilatation suggests that they may be useful biomarkers for TAA progression. The differences in diameter dilatation and life spans in male and female MU mice indicate that sex is an important consideration for managing thoracic aortic aneurysm in MFS. NEW & NOTEWORTHY Using a mouse model (Fbn1mgR/mgR = MU) of severe thoracic aortic aneurysm in Marfan syndrome (MFS), we found that male MU aorta had an accelerated time line and increased amounts of dilatation, stiffening, and extracellular matrix (ECM) remodeling compared with female MU aorta that may have contributed to an increased risk of fatigue failure with cyclic loading over time and a reduced life span. We suggest that aortic stiffness may provide useful information for clinical management of aneurysms in MFS.
MIN-102 (5-\[\[4-\[2-\[5-(1-Hydroxyethyl)-2-pyridinyl\]ethoxy\]phenyl\]methyl\]-2,4-thiazolidinedione hydrochloride (1:1)). Dosing is once daily at approximately the same time each morning throughout the entire treatment phase (48 weeks).
Women hospitalized for pre-eclampsia after 20 0/7 weeks of gestation. The diagnosis of preeclampsia include a combination of the following criteria: after 20 weeks of gestation in a previously normotensive woman, a diastolic blood pressure \> 90 mmHg recorded twice at least four hours apart or \> 110 mmHg, with proteinuria \> 300 mg/24h or \> 30 mg / mmol protein / urinary creatinine in a urine sample or factor (s) serious maternal / fetal (according to SOGC consensus ).
The present invention relates to an anti-itching agent that prevents itch of skin and a method for treating itching. An emulsion, which is produced when sebum and sweat continuously secreted are mixed, contains a stimulatory composition having aqueous and oily properties and can be a causative agent of itch. In addition, the emulsion can be a cell disorder composition. Furthermore, the emulsion causes itching and becomes a causative agent triggering and promoting dermatitis. The problem can be solved by blocking the emulsion by a skin-degenerative stratum corneum, which is formed by an action of an aluminum chloride and water, the aluminum chloride and a cyclodextrin. A polyphenol compound or a tannic acid can be also contained.
PURPOSE: A natural oriental medicinal crude drug composition and a method for preparing the same are provided to suppress histamine and cytokine and to prevent inflammation and secondary infection. CONSTITUTION: A natural oriental medicinal crude drug for treating atopy and acne contains: a Rehmanniae Radix fermentation extract prepared by fermenting Rehmanniae Radix at 35 Deg.C. for 3 months and extracting; a Rehmanniae Radix fermentation extract prepared by fermenting at 35 Deg.C. for 3 months and extracting; a garlic fermentation extract prepared by fermenting garlic at 35 Deg.C. for 3 months and extracting; and a Chinese matrimony vine fermentation extract prepared by fermenting Chinese matrimony vine at 35 Deg.C. for 3 months and extracting. [Reference numerals] (AA) Age; (BB) Before application; (CC) After application; (DD,EE) One year old female; (FF,GG) 26-Mar-11; (HH,II) 2 weeks later; (JJ,KK) 09-Apr-11
If the starting dose level in Part A.1 is tolerated, dose escalation in Part A.2 may be initiated on an optional basis. In Part A.2, niraparib is used at a higher fixed dose.
<P>PROBLEM TO BE SOLVED: To fundamentally inhibit mechanism of unwanted hair growth (i.e. unwanted hair) on human body, to realize safe epilation using a major naturally occurring substance, and to enable simultaneous achievement of skin beautification and weight reduction effects.  <P>SOLUTION: A hair growth inhibitor is composed of a pineapple-derived enzyme, i.e. bromelain, derived from a natural fruit which is hardly harmful to human body, actinidin enzyme, i.e. kiwi fruit extract, a fermented solution of soymilk and bittern. Further addition of aloe extract, kudzu root extract, chlorella extract water-soluble collagen, royal jelly extract, propolis extract, etc., which are compatible with the above-mentioned components, as skin beautification components enables simultaneous achievement of epilation and skin beautification. Further addition of noni extract, guarana extract, perilla oil, Coleus Forskohlii etc., which are safe, highly effective and compatible with the above-mentioned components, realizes weight reduction. Through this invention, hair growth inhibition, skin beautification and weight reduction, which are the three major beauty elements especially for women, can be extremely easily and effectively achieved.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
BACKGROUND: Recent research highlights the importance of muscular strength as a key factor in physical fitness, a strong indicator of overall mortality risk, and a vital target for preventing chronic diseases. This study used a proteome-wide Mendelian randomization analysis plus colocalization analysis for low hand grip strength to explore potential therapeutic targets for muscle weakness.
METHODS: We conducted two two-sample Mendelian randomization analyses from four cohorts to identify and validate the causal relationship between plasma proteins and low grip strength. We also employed bidirectional Mendelian randomization analysis with Steiger filtering, Bayesian co-localization, and phenotype scanning to detect reverse causality, thereby consolidating our Mendelian randomization findings. Downstream analyses were also undertaken of identified proteins, including knockout models, enrichment analyses, and protein-protein interaction networks. Finally, we assessed the druggability of the identified proteins.
RESULTS: At Bonferroni significance (P < 6.82 × 10-5), Mendelian randomization analysis revealed that three proteins were causally associated with low grip strength. Increased MGP (OR = 0.85) and HP (OR = 0.96) decreased the risk of low grip strength, whereas elevated ART4 (OR = 1.06) increased the risk of low grip strength. None of the three proteins had reverse causality with low grip strength. Bayesian co-localization suggested that MGP shared the same variant with low grip strength (coloc.abf-PPH4 = 0.826). Further downstream analyses showed that MGP, which is highly expressed in musculoskeletal system, is a potential novel target for muscle weakness.
CONCLUSIONS: The proteome-wide Mendelian randomization investigation identified three proteins associated with the risk of muscle weakness. MGP, HP, and ART4 deserve further investigation as potential therapeutic targets for muscle weakness.
IV infusion; once MTD and/or RD has been determined in Phase 1, expansion cohorts of approximately 30 patients (each cohort) with PVNS or dt-TGCT will be enrolled to characterize clinical activity and safety profile of the RD. Treatment is planned to continue for up to 24 weeks or 56 weeks.
BACKGROUND: Leaks following bariatric surgery, while rare, are potentially fatal due to risk of peritonitis and sepsis. Anastomotic leaks and gastro-gastric fistulae following Roux-En-Y gastric bypass (RYGB) as well as staple line leaks after sleeve gastrectomy have historically been treated multimodally with surgical drainage, aggressive antibiotic therapy, and more recently, endoscopically. Endoscopic clipping using over-the-scope clips and endoscopic suturing are two of the most common approaches used to achieve full thickness closure.
METHODS: A systematic literature search was performed in PubMed to identify articles on the use of endoscopic clipping or suturing for the treatment of leaks and fistulae following bariatric surgery. Studies focusing on stents, and those that incorporated multiple closure techniques simultaneously, were excluded. Literature review and meta-analysis were performed with the PRISMA guidelines.
RESULTS: Five studies with 61 patients that underwent over-the-scope clip (OTSC) closure were included. The pooled proportion of successful closure across the studies was 81.1% (95% CI 67.3 to 91.7). The successful closure rates were homogeneous (I2 = 39%, p = 0.15). Three studies with 92 patients that underwent endoscopic suturing were included. The weighted pooled proportion of successful closure across the studies was shown to be 22.4% (95% CI 14.6 to 31.3). The successful closure rates were homogeneous (I2 = 0%, p = 0.44). Three of the studies, totaling 34 patients, examining OTSC deployment reported data for reintervention rate. The weighted pooled proportion of reintervention across the studies was 35.0% (95% CI 11.7 to 64.7). We noticed statistically significant heterogeneity (I2 = 68%, p = 0.04). One study, with 20 patients examining endoscopic suturing, reported rate of repeat intervention 60%.
CONCLUSION: Observational reports show that patients managed with OTSC were more likely to experience healing of their defect than those managed with endoscopic suturing. Larger controlled studies comparing different closure devices for bariatric leaks should be carried out to better understand the ideal endoscopic approach to these complications.
OBJECTIVES: Worldwide emergence of clonal outbreaks caused by fluconazole-resistant (FLCR) and the recent emergence of echinocandin- and multidrug-resistant (ECR and MDR) Candida parapsilosis isolates pose serious threats to modern clinics. Conducting large-scale epidemiological studies aimed at determining the genetic composition and antifungal resistance rates is necessary to devise antifungal stewardship and infection control strategies at international, national and local levels. Despite being severely hit by outbreaks due to FLCR C. parapsilosis isolates, such knowledge at the national level is lacking in Türkiye. Herein, we conducted a prospective multicentre study involving five major clinical centres in Türkiye to determine antifungal resistance rates, underlying mechanisms and genetic composition of all isolates.
METHODS: In total, 341 isolates were collected from 265 patients including clinical information. Antifungal susceptibility testing against common antifungals was performed in addition to sequencing of ERG11 and FKS1. Last, isolates were genotyped with short tandem repeat (STR) genotyping to investigate potential nosocomial transmission.
RESULTS: The FLCR rate was 26.7% (91/341), out of which 75.8% (69/91) harboured the ERG11Y132F mutation. Patients infected with FLCR isolates had a higher mortality rate compared to their susceptible counterparts (49% for FLCR vs. 42% for susceptible). ECR rate was 2.1% (7/341) and isolates carried FKS1F652L/R658G/W1370R mutations. Concerningly, four ECR isolates were MDR. FLCR isolates grouped in distinct clusters without evidence of inter-hospital transmission, whereas large clusters containing susceptible isolates from all centres were noted.
CONCLUSION: Overall, the increasing prevalence of FLCR C. parapsilosis at national level and the emergence of ECR and MDR isolates pose serious clinical challenges in Türkiye. Therefore, conducting large-scale epidemiological studies are critical to determine the trend of antifungal resistance and to tailor pertinent antifungal stewardship and infection control strategies to effectively curb the spread of drug-resistant C. parapsilosis.
The active ingredient in GATTEX (teduglutide) for injection is teduglutide, which is a 33 amino acid glucagon-like peptide-2 (GLP-2) analog manufactured using a strain of Escherichia coli modified by recombinant DNA technology. The chemical composition of teduglutide is L-histidyl-L-glycyl-L-aspartyl-L-glycyl-L-seryl-L-phenylalanyl-L-seryl-L-aspartyl-L-glutamyl-L-methionyl-L-asparaginyl-L-threonyl-L-isoleucyl-L-leucyl-L-aspartyl-L-asparaginyl-L-leucyl-L-alanyl-L-alanyl-L-arginyl-L-aspartyl-L-phenylalanyl-L-isoleucyl-L-asparaginyl-L-tryptophanyl-L-leucyl-L-isoleucyl-L-glutaminyl-L-threonyl-L-lysyl-L-isoleucyl-L-threonyl-L-aspartic acid. The structural formula is:

Figure 1: Structural formula of teduglutide

Teduglutide has a molecular weight of 3752 Daltons. Teduglutide drug substance is a clear, colorless to light-straw–colored liquid.

Each single-dose vial of GATTEX contains 5 mg of teduglutide as a white lyophilized powder for reconstitution and administration by subcutaneous injection. In addition to the active pharmaceutical ingredient (teduglutide), each vial of GATTEX contains 3.434 mg dibasic sodium phosphate heptahydrate, 3.88 mg L-histidine, 15 mg mannitol, and 0.644 mg monobasic sodium phosphate monohydrate as excipients. No preservatives are present.

At the time of administration, the lyophilized powder is reconstituted with 0.5 mL of Sterile Water for Injection, which is provided in a single-dose prefilled syringe. A 10 mg/mL sterile solution is obtained after reconstitution. Up to 0.38 mL of the reconstituted solution which contains 3.8 mg of teduglutide can be withdrawn for subcutaneous injection upon reconstitution.
Solid forms of nifedipine (I), which have higher bioavailability and lower volume, are prepd. by dissolving or suspending I in a solvent with an appropriate solids (polyvinylpyrrolidinone, methyl cellulose, hydroxy propyl cellulose, etc.) and removing the solvent.  Thus, 1 g nifedipine, 2 g poly vinylpyrrolidinone and 1 g Na lauryl sulfate were dissolved in 60 g CHCH3-EtOH (9:1).  Spray-drying gave a powder which, on oral administration to dogs, yielded plasma I concns. comparable with those given by a std. I prepn.
For most patients with illness of mild to moderate severity, a starting daily dose of 75 mg is recommended. Dosage may subsequently be increased or decreased at appropriate intervals and according to individual response. The usual optimum dose range is 75 mg/day to 150 mg/day.

In more severely ill patients higher doses may be required with subsequent gradual increase to 300 mg/day if necessary. Additional therapeutic effect is rarely to be obtained by exceeding a dose of 300 mg/day.

In patients with very mild symptomatology or emotional symptoms accompanying organic disease, lower doses may suffice. Some of these patients have been controlled on doses as low as 25 to 50 mg/day.

The total daily dosage of doxepin hydrochloride may be given on a divided or once-a-day dosage schedule. If the once-a-day schedule is employed, the maximum recommended dose is 150 mg/day. This dose may be given at bedtime. The 150 mg capsule strength is intended for maintenance therapy only and is not recommended for initiation of treatment.

Anti-anxiety effect is apparent before the antidepressant effect. Optimal antidepressant effect may not be evident for two to three weeks.
Patients who are implanted CRT devices will be enrolled in the study. Once implanted, all patients will be followed at every 3 months for the first 12 months from the implant. The responder/non-responder evaluation will occur at 6 months from the implant date. The criteria used for determining the response to CRT will be captured.

During the office follow-up visits, arrhythmic episode diagnoses, device data and stored electrogram will be collected. All clinical events such as hospitalization for heart failure (HF), all-cause hospitalizations, and all-cause death will also be collected. For patients who are non-responders to CRT, any re-optimization of the device, i.e., atrioventricular and ventricle-to-ventricle interval optimization, left ventricular (LV) lead repositioning and pacing vector reconfiguration as well as modified/new clinical therapies administered in an attempt to improve HF condition will be collected.
Mortality in infarct-related as well as heart failure-associated cardiogenic shock remains high, reaching 40-50% depending on the etiology and severity of cardiogenic shock. Percutaneous active mechanical circulatory support devices including veno-arterial extracorporeal membrane oxygenation (VA-ECMO) and microaxial left ventricular mechanical circulatory support devices are rapidly evolving in their use. However, evidence of VA-ECMO therapy has only recently emerged and showed no benefit for mortality, with an associated higher complication rate. Evidence for microaxial left ventricular mechanical circulatory support devices such as the Impella pump (Abiomed, Danvers/MA, USA) is limited. The current article aims to give an overview of the basics of VA-ECMO therapy and microaxial left ventricular mechanical circulatory support devices, the current evidence, ongoing trials, patient selection, and potential complications. This article is freely available.
Participants in this arm will complete baseline and follow-up visits (approximately 3-months after) and Mid-intervention safety checks. They will attend the Cognitive Rehabilitation program that will meet weekly for 8 weeks. Each session will last one-and-a-half hours.
Skeletal myoblasts are an attractive cell type for transplantation since they are autologous and resistant to ischemia. However, clinical trials of myoblasts transplantation in heart failure have been plagued by ventricular tachy-arrhythmias and sudden cardiac death. The pathogenesis of these arrhythmias is poorly understood, but may be related to the fact that skeletal muscle cells, unlike heart cells, are electrically isolated by the absence of gap junctions. An in vitro model of myoblasts transplantation into cardiomyocyte monolayers can be used to investigate the mechanisms of transplant-associated arrhythmias. Co-cultures of human skeletal myoblasts and rat cardiomyocytes result in reentrant arrhythmias (spiral waves) that reproduce the features of ventricular tachycardia seen in patients receiving myoblasts transplants. These arrhythmias can be terminated by nitrendipine, an L-type calcium channel Mocker, but not by the Na channel blocker lidocaine. Genetic modification of myoblasts to stably express the gap junction protein connexin 43 decreases arrhythmogenicity in co-cultures. It similarly can be used to increase the safety of myoblasts transplantation in patients.
PURPOSE: A cosmetic composition containing one or more selected from a Veratrum nigrum L. extract and Potentilla chinensis Ser. extract having a melanogenesis-inhibiting effect is provided. The composition exhibits a skin whitening effect and reduced pigmentation without adverse effect on the skin. CONSTITUTION: This cosmetic composition contains 0.0001 to 10.0% by weight of a Veratrum nigrum L. extract and Potentilla chinensis Ser. extract(dry basis) as an effective component. The Veratrum nigrum L. extract and Potentilla chinensis Ser. extract are obtained by extracting with water, C1-4 lower alcohol, ethylacetate or acetone one or more times and freeze drying or spay drying after reduced pressure distillation.
Heat stress (HS) induces various pathophysiological responses in the brain, encompassing neuroinflammation and cognitive impairments. Although taurine has been reported to possess anti-inflammatory and cognitive-enhancing properties, its role and mechanisms in HS-induced cognitive impairment remain unclear. This study supplemented mice exposed to HS with taurine to assess its effect on cognitive function in a HS-induced mouse model. The results revealed that taurine ameliorated cognitive deficits following HS in mice and mitigated HS-induced astrocyte and microglia activation as well as blood-brain barrier (BBB) damage in the hippocampus. Mechanistically, Mechanistically, transcriptome sequencing was employed to identify that taurine regulates neuronal PAS domain protein (Npas4) and lipocalin 2 (Lcn2) during HS. Taurine was found to modulate hippocampal inflammation and influence cognitive function by upregulating Npas4 and downregulating Lcn2 after HS. Subsequently, molecular docking and AnimalTFDB database calculations were conducted, revealing that taurine might regulate the expression of Npas4 and Lcn2 by modulating the regulatory transcription factors (TFs) RE1 silencing transcription factor (REST) and nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (NFKB1). Our findings demonstrate that taurine enhances the recovery of cognitive function through Npas4 and Lcn2 following HS, providing a theoretical basis for the clinical application of taurine in preventing or treating HS-induced cognitive impairment.
PURPOSE:To separate the novel protein contained in serum by bringing the serum protein contained in the serum of an animal into contact with deoxyribonuclease I (DNaseI) so as to be adsorbed thereto and eluting the protein by using a specific eluting agent. CONSTITUTION:The serum of the animal is first brought into contact with the DNaseI so as to adsorb the serum protein contained in the serum to the DNaseI. The adsorbed serum protein is eluted by using at least one kind among ethylene glycol bis-beta-aminoethyl ether tetraacetic acid, guanidine hydrochloride, urea and sodium thiocyanate. The resultant serum protein is a novel compd. and is the protein (29K protein) having affinity to the DNaseI and having about 29,000mol.wt. Such 29K protein is applicable for clinical inspection as an index for various diseases.
FIELD: biotechnology.SUBSTANCE: invention relates to biotechnology. Disclosed is an immunoconjugate for the specific induction of T cell cytotoxicity against target cells. The immunoconjugate includes at least one naturally occurring peptide inducing a T cell response. The peptide is capable of being presented through MHC class I connected to an antibody that binds a target cell via a cleavable bond. The peptide inducing a T cell response has at least one cysteine ​​residue and is covalently linked to the antibody via a disulfide bond. Also disclosed are methods for preparing an immunoconjugate and using it to treat a tumour.EFFECT: effective tumour treatment.12 cl, 25 dwg, 4 tbl, 11 ex
The target International Normalized Ratio (INR) is 1.8. Warfarin initiation is via Pharmacogenetic dosing.
NEW MATERIAL:A compound expressed by formula I (R<1> is 3-7C unsaturated alkyl and unsaturated cyclic alkyl; R<2> is H or halogen; R<3> is H or lower alkyl; X is carboxyl), salt, ester or amide thereof. EXAMPLE:[2-(1-Cyclohexenyl)-4-oxo-4H-[1H]-benzopyran-8-yl]acetic acid. USE:A medicine which is an active ingredient of antitumor agents, orally or parenterally used with low toxicity and applicable in a dose of 0.01-200mg/kg body weight/day expressed in terms of the active ingredient in 1-3 divided portion or at an interval of 2-7 days. PREPARATION:For example, a compound expressed by formula II is reacted with an ester expressed by formula III (R<4> is hydrogenated R<1>) in the presence of a base to provide a compound expressed by formula IV, which is subsequently cyclized with an acid to afford a compound expressed by formula VI. The resultant compound expressed by formula VI is subsequently brominated with a brominating agent to form a compound expressed by formula VII, which is then subjected to cyanogenation reaction to provide a compound expressed by formula VIII. The obtained compound expressed by formula VIII is finally solvolyzed to afford the aimed compound expressed by formula I.